Skip to main content
Erschienen in: Nuclear Medicine and Molecular Imaging 4/2021

02.06.2021 | Interesting image

Mismatched Imaging Findings of Prostate Cancer Diagnosis: 68 Ga-PSMA PET/CT vs mpMRI

verfasst von: Egesta Lopci, Piergiuseppe Colombo, Massimo Lazzeri

Erschienen in: Nuclear Medicine and Molecular Imaging | Ausgabe 4/2021

Einloggen, um Zugang zu erhalten

Abstract

Multiparametric magnetic resonance imaging (mpMRI) is the modality of choice for initial diagnosis of prostate cancer (PCa), including biopsy-naïve patients. Nevertheless, clinicians must be aware of the possibility that up to one-fourth of clinically significant cancers might be missed by the modality. Acknowledgment of this occurrence and the increased availability of 68 Ga-PSMA PET/CT in clinical routine, open the door to new, fascinating, indications for this functional modality in the context of PCa detection. With the case herein illustrated, we report a paradigmatic example of mismatch findings between PET/CT and mpMRI better elucidating the potential indication.
Literatur
1.
Zurück zum Zitat Lopci E, Saita A, Lazzeri M, et al. 68Ga-PSMA positron emission tomography/computerized tomography for primary diagnosis of prostate cancer in men with contraindications to or negative multiparametric magnetic resonance imaging: a prospective observational study. J Urol. 2018;200:95–103.CrossRef Lopci E, Saita A, Lazzeri M, et al. 68Ga-PSMA positron emission tomography/computerized tomography for primary diagnosis of prostate cancer in men with contraindications to or negative multiparametric magnetic resonance imaging: a prospective observational study. J Urol. 2018;200:95–103.CrossRef
2.
Zurück zum Zitat Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1 screening diagnosis and local treatment with curative intent. Eur Urol. 2017;71:618–29.CrossRef Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1 screening diagnosis and local treatment with curative intent. Eur Urol. 2017;71:618–29.CrossRef
3.
Zurück zum Zitat Mottet N, Roderick CN, van den Bergh, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on prostate cancer—2020 Update.Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2020;S0302–2838(20)30769–7. Mottet N, Roderick CN, van den Bergh, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on prostate cancer—2020 Update.Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2020;S0302–2838(20)30769–7.
4.
Zurück zum Zitat Lopci E, Lughezzani G, Castello A, et al. Prospective evaluation of 68Ga-labeled prostate-specific membrane antigen ligand positron emission tomography/computed tomography in primary prostate cancer diagnosis. Eur Urol Focus. 2020;S2405–4569(20):30092–4. Lopci E, Lughezzani G, Castello A, et al. Prospective evaluation of 68Ga-labeled prostate-specific membrane antigen ligand positron emission tomography/computed tomography in primary prostate cancer diagnosis. Eur Urol Focus. 2020;S2405–4569(20):30092–4.
Metadaten
Titel
Mismatched Imaging Findings of Prostate Cancer Diagnosis: 68 Ga-PSMA PET/CT vs mpMRI
verfasst von
Egesta Lopci
Piergiuseppe Colombo
Massimo Lazzeri
Publikationsdatum
02.06.2021
Verlag
Springer Singapore
Erschienen in
Nuclear Medicine and Molecular Imaging / Ausgabe 4/2021
Print ISSN: 1869-3474
Elektronische ISSN: 1869-3482
DOI
https://doi.org/10.1007/s13139-021-00701-x

Weitere Artikel der Ausgabe 4/2021

Nuclear Medicine and Molecular Imaging 4/2021 Zur Ausgabe